nodes	percent_of_prediction	percent_of_DWPC	metapath
Emtricitabine—DCK—Doxorubicin—Epirubicin—thyroid cancer	0.0121	0.519	CbGdCrCtD
Emtricitabine—DCK—Epirubicin—Doxorubicin—thyroid cancer	0.0112	0.481	CbGdCrCtD
Emtricitabine—Sinusitis—Vandetanib—thyroid cancer	0.00513	0.00525	CcSEcCtD
Emtricitabine—Urinary tract disorder—Vandetanib—thyroid cancer	0.00484	0.00496	CcSEcCtD
Emtricitabine—Urethral disorder—Vandetanib—thyroid cancer	0.00481	0.00492	CcSEcCtD
Emtricitabine—Mediastinal disorder—Vandetanib—thyroid cancer	0.00442	0.00453	CcSEcCtD
Emtricitabine—Hypokalaemia—Sorafenib—thyroid cancer	0.00435	0.00446	CcSEcCtD
Emtricitabine—Vesiculobullous rash—Epirubicin—thyroid cancer	0.00434	0.00445	CcSEcCtD
Emtricitabine—Breast disorder—Sorafenib—thyroid cancer	0.00432	0.00443	CcSEcCtD
Emtricitabine—Mental disorder—Vandetanib—thyroid cancer	0.0043	0.0044	CcSEcCtD
Emtricitabine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00428	0.00438	CcSEcCtD
Emtricitabine—Malnutrition—Vandetanib—thyroid cancer	0.00427	0.00437	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00422	0.00432	CcSEcCtD
Emtricitabine—Hypophosphataemia—Epirubicin—thyroid cancer	0.00419	0.00429	CcSEcCtD
Emtricitabine—Skin hyperpigmentation—Epirubicin—thyroid cancer	0.00409	0.00419	CcSEcCtD
Emtricitabine—Pancreatitis—Sorafenib—thyroid cancer	0.00405	0.00415	CcSEcCtD
Emtricitabine—Vesiculobullous rash—Doxorubicin—thyroid cancer	0.00402	0.00412	CcSEcCtD
Emtricitabine—Hypophosphataemia—Doxorubicin—thyroid cancer	0.00388	0.00397	CcSEcCtD
Emtricitabine—Neutropenia—Sorafenib—thyroid cancer	0.00387	0.00396	CcSEcCtD
Emtricitabine—Skin hyperpigmentation—Doxorubicin—thyroid cancer	0.00379	0.00388	CcSEcCtD
Emtricitabine—Weight decreased—Sorafenib—thyroid cancer	0.00374	0.00383	CcSEcCtD
Emtricitabine—Cough—Vandetanib—thyroid cancer	0.00373	0.00382	CcSEcCtD
Emtricitabine—Pneumonia—Sorafenib—thyroid cancer	0.00371	0.0038	CcSEcCtD
Emtricitabine—Infestation NOS—Sorafenib—thyroid cancer	0.00369	0.00377	CcSEcCtD
Emtricitabine—Infestation—Sorafenib—thyroid cancer	0.00369	0.00377	CcSEcCtD
Emtricitabine—Arthralgia—Vandetanib—thyroid cancer	0.00364	0.00372	CcSEcCtD
Emtricitabine—Renal failure—Sorafenib—thyroid cancer	0.00362	0.00371	CcSEcCtD
Emtricitabine—Anxiety—Vandetanib—thyroid cancer	0.00362	0.00371	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00361	0.0037	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00361	0.0037	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00349	0.00357	CcSEcCtD
Emtricitabine—Infection—Vandetanib—thyroid cancer	0.00346	0.00355	CcSEcCtD
Emtricitabine—Hepatomegaly—Epirubicin—thyroid cancer	0.00344	0.00352	CcSEcCtD
Emtricitabine—Nervous system disorder—Vandetanib—thyroid cancer	0.00342	0.0035	CcSEcCtD
Emtricitabine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00341	0.00349	CcSEcCtD
Emtricitabine—Skin disorder—Vandetanib—thyroid cancer	0.00339	0.00347	CcSEcCtD
Emtricitabine—Urinary tract disorder—Sorafenib—thyroid cancer	0.00327	0.00335	CcSEcCtD
Emtricitabine—Neuritis—Epirubicin—thyroid cancer	0.00326	0.00334	CcSEcCtD
Emtricitabine—Connective tissue disorder—Sorafenib—thyroid cancer	0.00325	0.00333	CcSEcCtD
Emtricitabine—Urethral disorder—Sorafenib—thyroid cancer	0.00324	0.00332	CcSEcCtD
Emtricitabine—Hepatomegaly—Doxorubicin—thyroid cancer	0.00318	0.00326	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00318	0.00325	CcSEcCtD
Emtricitabine—Insomnia—Vandetanib—thyroid cancer	0.00315	0.00323	CcSEcCtD
Emtricitabine—Paraesthesia—Vandetanib—thyroid cancer	0.00313	0.0032	CcSEcCtD
Emtricitabine—Otitis media—Epirubicin—thyroid cancer	0.00313	0.0032	CcSEcCtD
Emtricitabine—Dyspnoea—Vandetanib—thyroid cancer	0.00311	0.00318	CcSEcCtD
Emtricitabine—Dyspepsia—Vandetanib—thyroid cancer	0.00307	0.00314	CcSEcCtD
Emtricitabine—Rash pustular—Epirubicin—thyroid cancer	0.00305	0.00313	CcSEcCtD
Emtricitabine—Neuritis—Doxorubicin—thyroid cancer	0.00302	0.00309	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00301	0.00308	CcSEcCtD
Emtricitabine—Glycosuria—Epirubicin—thyroid cancer	0.00301	0.00308	CcSEcCtD
Emtricitabine—Fatigue—Vandetanib—thyroid cancer	0.003	0.00308	CcSEcCtD
Emtricitabine—Immune system disorder—Sorafenib—thyroid cancer	0.00299	0.00306	CcSEcCtD
Emtricitabine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00298	0.00305	CcSEcCtD
Emtricitabine—Pain—Vandetanib—thyroid cancer	0.00298	0.00305	CcSEcCtD
Emtricitabine—Mental disorder—Sorafenib—thyroid cancer	0.0029	0.00297	CcSEcCtD
Emtricitabine—Otitis media—Doxorubicin—thyroid cancer	0.00289	0.00296	CcSEcCtD
Emtricitabine—Malnutrition—Sorafenib—thyroid cancer	0.00288	0.00295	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00285	0.00292	CcSEcCtD
Emtricitabine—Rash pustular—Doxorubicin—thyroid cancer	0.00283	0.00289	CcSEcCtD
Emtricitabine—Glycosuria—Doxorubicin—thyroid cancer	0.00278	0.00285	CcSEcCtD
Emtricitabine—Body temperature increased—Vandetanib—thyroid cancer	0.00276	0.00282	CcSEcCtD
Emtricitabine—Abdominal pain—Vandetanib—thyroid cancer	0.00276	0.00282	CcSEcCtD
Emtricitabine—Skin discolouration—Epirubicin—thyroid cancer	0.0027	0.00276	CcSEcCtD
Emtricitabine—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.00268	0.00274	CcSEcCtD
Emtricitabine—Anaemia—Sorafenib—thyroid cancer	0.00266	0.00273	CcSEcCtD
Emtricitabine—Cough increased—Epirubicin—thyroid cancer	0.00266	0.00272	CcSEcCtD
Emtricitabine—Angioedema—Sorafenib—thyroid cancer	0.00263	0.0027	CcSEcCtD
Emtricitabine—Creatinine increased—Epirubicin—thyroid cancer	0.00256	0.00262	CcSEcCtD
Emtricitabine—Bone pain—Epirubicin—thyroid cancer	0.00254	0.0026	CcSEcCtD
Emtricitabine—Cough—Sorafenib—thyroid cancer	0.00251	0.00257	CcSEcCtD
Emtricitabine—Inflammation—Epirubicin—thyroid cancer	0.00251	0.00257	CcSEcCtD
Emtricitabine—Asthenia—Vandetanib—thyroid cancer	0.0025	0.00256	CcSEcCtD
Emtricitabine—Skin discolouration—Doxorubicin—thyroid cancer	0.00249	0.00255	CcSEcCtD
Emtricitabine—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.00248	0.00254	CcSEcCtD
Emtricitabine—Pruritus—Vandetanib—thyroid cancer	0.00247	0.00252	CcSEcCtD
Emtricitabine—Cough increased—Doxorubicin—thyroid cancer	0.00246	0.00252	CcSEcCtD
Emtricitabine—Arthralgia—Sorafenib—thyroid cancer	0.00245	0.00251	CcSEcCtD
Emtricitabine—Myalgia—Sorafenib—thyroid cancer	0.00245	0.00251	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00244	0.00249	CcSEcCtD
Emtricitabine—Abnormal dreams—Epirubicin—thyroid cancer	0.00241	0.00246	CcSEcCtD
Emtricitabine—Diarrhoea—Vandetanib—thyroid cancer	0.00238	0.00244	CcSEcCtD
Emtricitabine—Creatinine increased—Doxorubicin—thyroid cancer	0.00237	0.00242	CcSEcCtD
Emtricitabine—Bone pain—Doxorubicin—thyroid cancer	0.00235	0.00241	CcSEcCtD
Emtricitabine—Infection—Sorafenib—thyroid cancer	0.00234	0.00239	CcSEcCtD
Emtricitabine—Inflammation—Doxorubicin—thyroid cancer	0.00232	0.00238	CcSEcCtD
Emtricitabine—Nervous system disorder—Sorafenib—thyroid cancer	0.00231	0.00236	CcSEcCtD
Emtricitabine—Dizziness—Vandetanib—thyroid cancer	0.0023	0.00236	CcSEcCtD
Emtricitabine—Thrombocytopenia—Sorafenib—thyroid cancer	0.0023	0.00236	CcSEcCtD
Emtricitabine—Neuropathy—Epirubicin—thyroid cancer	0.00229	0.00234	CcSEcCtD
Emtricitabine—Skin disorder—Sorafenib—thyroid cancer	0.00228	0.00234	CcSEcCtD
Emtricitabine—Abnormal dreams—Doxorubicin—thyroid cancer	0.00223	0.00228	CcSEcCtD
Emtricitabine—Vomiting—Vandetanib—thyroid cancer	0.00222	0.00227	CcSEcCtD
Emtricitabine—Rash maculo-papular—Epirubicin—thyroid cancer	0.00221	0.00227	CcSEcCtD
Emtricitabine—Rash—Vandetanib—thyroid cancer	0.0022	0.00225	CcSEcCtD
Emtricitabine—Dermatitis—Vandetanib—thyroid cancer	0.0022	0.00225	CcSEcCtD
Emtricitabine—Headache—Vandetanib—thyroid cancer	0.00218	0.00224	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00214	0.00219	CcSEcCtD
Emtricitabine—Neuropathy—Doxorubicin—thyroid cancer	0.00212	0.00217	CcSEcCtD
Emtricitabine—Dyspnoea—Sorafenib—thyroid cancer	0.0021	0.00215	CcSEcCtD
Emtricitabine—Nausea—Vandetanib—thyroid cancer	0.00207	0.00212	CcSEcCtD
Emtricitabine—Dyspepsia—Sorafenib—thyroid cancer	0.00207	0.00212	CcSEcCtD
Emtricitabine—Rash maculo-papular—Doxorubicin—thyroid cancer	0.00205	0.0021	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00203	0.00208	CcSEcCtD
Emtricitabine—Fatigue—Sorafenib—thyroid cancer	0.00203	0.00208	CcSEcCtD
Emtricitabine—Pain—Sorafenib—thyroid cancer	0.00201	0.00206	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00192	0.00197	CcSEcCtD
Emtricitabine—Renal failure acute—Epirubicin—thyroid cancer	0.00191	0.00196	CcSEcCtD
Emtricitabine—Urticaria—Sorafenib—thyroid cancer	0.00187	0.00191	CcSEcCtD
Emtricitabine—Body temperature increased—Sorafenib—thyroid cancer	0.00186	0.0019	CcSEcCtD
Emtricitabine—Abdominal pain—Sorafenib—thyroid cancer	0.00186	0.0019	CcSEcCtD
Emtricitabine—Renal impairment—Epirubicin—thyroid cancer	0.00186	0.0019	CcSEcCtD
Emtricitabine—Dermatitis bullous—Epirubicin—thyroid cancer	0.00185	0.00189	CcSEcCtD
Emtricitabine—Renal failure acute—Doxorubicin—thyroid cancer	0.00177	0.00181	CcSEcCtD
Emtricitabine—Hypersensitivity—Sorafenib—thyroid cancer	0.00173	0.00177	CcSEcCtD
Emtricitabine—Renal impairment—Doxorubicin—thyroid cancer	0.00172	0.00176	CcSEcCtD
Emtricitabine—Dermatitis bullous—Doxorubicin—thyroid cancer	0.00171	0.00175	CcSEcCtD
Emtricitabine—Asthenia—Sorafenib—thyroid cancer	0.00169	0.00173	CcSEcCtD
Emtricitabine—Pruritus—Sorafenib—thyroid cancer	0.00166	0.0017	CcSEcCtD
Emtricitabine—Blood creatinine increased—Epirubicin—thyroid cancer	0.00166	0.0017	CcSEcCtD
Emtricitabine—Hypokalaemia—Epirubicin—thyroid cancer	0.00161	0.00165	CcSEcCtD
Emtricitabine—Diarrhoea—Sorafenib—thyroid cancer	0.00161	0.00165	CcSEcCtD
Emtricitabine—Breast disorder—Epirubicin—thyroid cancer	0.0016	0.00164	CcSEcCtD
Emtricitabine—Nasopharyngitis—Epirubicin—thyroid cancer	0.00158	0.00162	CcSEcCtD
Emtricitabine—Muscular weakness—Epirubicin—thyroid cancer	0.00156	0.0016	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00156	0.0016	CcSEcCtD
Emtricitabine—Dizziness—Sorafenib—thyroid cancer	0.00155	0.00159	CcSEcCtD
Emtricitabine—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00153	0.00157	CcSEcCtD
Emtricitabine—Pancreatitis—Epirubicin—thyroid cancer	0.0015	0.00153	CcSEcCtD
Emtricitabine—Vomiting—Sorafenib—thyroid cancer	0.00149	0.00153	CcSEcCtD
Emtricitabine—Hypokalaemia—Doxorubicin—thyroid cancer	0.00149	0.00152	CcSEcCtD
Emtricitabine—Rash—Sorafenib—thyroid cancer	0.00148	0.00152	CcSEcCtD
Emtricitabine—Dermatitis—Sorafenib—thyroid cancer	0.00148	0.00152	CcSEcCtD
Emtricitabine—Breast disorder—Doxorubicin—thyroid cancer	0.00148	0.00151	CcSEcCtD
Emtricitabine—Headache—Sorafenib—thyroid cancer	0.00147	0.00151	CcSEcCtD
Emtricitabine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00146	0.0015	CcSEcCtD
Emtricitabine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00144	0.00148	CcSEcCtD
Emtricitabine—Muscular weakness—Doxorubicin—thyroid cancer	0.00144	0.00148	CcSEcCtD
Emtricitabine—Neutropenia—Epirubicin—thyroid cancer	0.00143	0.00146	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00142	0.00145	CcSEcCtD
Emtricitabine—Nausea—Sorafenib—thyroid cancer	0.0014	0.00143	CcSEcCtD
Emtricitabine—Pancreatitis—Doxorubicin—thyroid cancer	0.00139	0.00142	CcSEcCtD
Emtricitabine—Weight decreased—Epirubicin—thyroid cancer	0.00138	0.00142	CcSEcCtD
Emtricitabine—Hyperglycaemia—Epirubicin—thyroid cancer	0.00138	0.00141	CcSEcCtD
Emtricitabine—Pneumonia—Epirubicin—thyroid cancer	0.00137	0.0014	CcSEcCtD
Emtricitabine—Infestation NOS—Epirubicin—thyroid cancer	0.00136	0.00139	CcSEcCtD
Emtricitabine—Infestation—Epirubicin—thyroid cancer	0.00136	0.00139	CcSEcCtD
Emtricitabine—Renal failure—Epirubicin—thyroid cancer	0.00134	0.00137	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00134	0.00137	CcSEcCtD
Emtricitabine—Urinary tract infection—Epirubicin—thyroid cancer	0.00132	0.00136	CcSEcCtD
Emtricitabine—Neutropenia—Doxorubicin—thyroid cancer	0.00132	0.00135	CcSEcCtD
Emtricitabine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00131	0.00135	CcSEcCtD
Emtricitabine—Haematuria—Epirubicin—thyroid cancer	0.0013	0.00133	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00129	0.00132	CcSEcCtD
Emtricitabine—Weight decreased—Doxorubicin—thyroid cancer	0.00128	0.00131	CcSEcCtD
Emtricitabine—Sinusitis—Epirubicin—thyroid cancer	0.00128	0.00131	CcSEcCtD
Emtricitabine—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00128	0.00131	CcSEcCtD
Emtricitabine—Pneumonia—Doxorubicin—thyroid cancer	0.00127	0.0013	CcSEcCtD
Emtricitabine—Infestation NOS—Doxorubicin—thyroid cancer	0.00126	0.00129	CcSEcCtD
Emtricitabine—Infestation—Doxorubicin—thyroid cancer	0.00126	0.00129	CcSEcCtD
Emtricitabine—Renal failure—Doxorubicin—thyroid cancer	0.00124	0.00127	CcSEcCtD
Emtricitabine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00124	0.00127	CcSEcCtD
Emtricitabine—Rhinitis—Epirubicin—thyroid cancer	0.00123	0.00126	CcSEcCtD
Emtricitabine—Urinary tract infection—Doxorubicin—thyroid cancer	0.00123	0.00125	CcSEcCtD
Emtricitabine—Hepatitis—Epirubicin—thyroid cancer	0.00122	0.00125	CcSEcCtD
Emtricitabine—Pharyngitis—Epirubicin—thyroid cancer	0.00121	0.00124	CcSEcCtD
Emtricitabine—Urinary tract disorder—Epirubicin—thyroid cancer	0.00121	0.00124	CcSEcCtD
Emtricitabine—Haematuria—Doxorubicin—thyroid cancer	0.0012	0.00123	CcSEcCtD
Emtricitabine—Connective tissue disorder—Epirubicin—thyroid cancer	0.0012	0.00123	CcSEcCtD
Emtricitabine—Urethral disorder—Epirubicin—thyroid cancer	0.0012	0.00123	CcSEcCtD
Emtricitabine—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00119	0.00122	CcSEcCtD
Emtricitabine—Sinusitis—Doxorubicin—thyroid cancer	0.00118	0.00121	CcSEcCtD
Emtricitabine—Rhinitis—Doxorubicin—thyroid cancer	0.00113	0.00116	CcSEcCtD
Emtricitabine—Hepatitis—Doxorubicin—thyroid cancer	0.00113	0.00116	CcSEcCtD
Emtricitabine—Pharyngitis—Doxorubicin—thyroid cancer	0.00112	0.00115	CcSEcCtD
Emtricitabine—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00112	0.00114	CcSEcCtD
Emtricitabine—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00111	0.00114	CcSEcCtD
Emtricitabine—Urethral disorder—Doxorubicin—thyroid cancer	0.00111	0.00114	CcSEcCtD
Emtricitabine—Immune system disorder—Epirubicin—thyroid cancer	0.0011	0.00113	CcSEcCtD
Emtricitabine—Mediastinal disorder—Epirubicin—thyroid cancer	0.0011	0.00113	CcSEcCtD
Emtricitabine—Mental disorder—Epirubicin—thyroid cancer	0.00107	0.0011	CcSEcCtD
Emtricitabine—Malnutrition—Epirubicin—thyroid cancer	0.00106	0.00109	CcSEcCtD
Emtricitabine—Back pain—Epirubicin—thyroid cancer	0.00103	0.00105	CcSEcCtD
Emtricitabine—Immune system disorder—Doxorubicin—thyroid cancer	0.00102	0.00105	CcSEcCtD
Emtricitabine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00102	0.00104	CcSEcCtD
Emtricitabine—Mental disorder—Doxorubicin—thyroid cancer	0.000991	0.00102	CcSEcCtD
Emtricitabine—Malnutrition—Doxorubicin—thyroid cancer	0.000985	0.00101	CcSEcCtD
Emtricitabine—Anaemia—Epirubicin—thyroid cancer	0.000984	0.00101	CcSEcCtD
Emtricitabine—Back pain—Doxorubicin—thyroid cancer	0.000953	0.000976	CcSEcCtD
Emtricitabine—Cough—Epirubicin—thyroid cancer	0.000929	0.000951	CcSEcCtD
Emtricitabine—Anaemia—Doxorubicin—thyroid cancer	0.00091	0.000932	CcSEcCtD
Emtricitabine—Myalgia—Epirubicin—thyroid cancer	0.000906	0.000928	CcSEcCtD
Emtricitabine—Arthralgia—Epirubicin—thyroid cancer	0.000906	0.000928	CcSEcCtD
Emtricitabine—Anxiety—Epirubicin—thyroid cancer	0.000903	0.000925	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0009	0.000922	CcSEcCtD
Emtricitabine—Infection—Epirubicin—thyroid cancer	0.000863	0.000884	CcSEcCtD
Emtricitabine—Cough—Doxorubicin—thyroid cancer	0.00086	0.00088	CcSEcCtD
Emtricitabine—Nervous system disorder—Epirubicin—thyroid cancer	0.000852	0.000872	CcSEcCtD
Emtricitabine—Thrombocytopenia—Epirubicin—thyroid cancer	0.000851	0.000871	CcSEcCtD
Emtricitabine—Skin disorder—Epirubicin—thyroid cancer	0.000844	0.000864	CcSEcCtD
Emtricitabine—Myalgia—Doxorubicin—thyroid cancer	0.000839	0.000859	CcSEcCtD
Emtricitabine—Arthralgia—Doxorubicin—thyroid cancer	0.000839	0.000859	CcSEcCtD
Emtricitabine—Anxiety—Doxorubicin—thyroid cancer	0.000836	0.000856	CcSEcCtD
Emtricitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000833	0.000853	CcSEcCtD
Emtricitabine—Infection—Doxorubicin—thyroid cancer	0.000799	0.000818	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000792	0.00081	CcSEcCtD
Emtricitabine—Nervous system disorder—Doxorubicin—thyroid cancer	0.000788	0.000807	CcSEcCtD
Emtricitabine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000787	0.000806	CcSEcCtD
Emtricitabine—Insomnia—Epirubicin—thyroid cancer	0.000786	0.000805	CcSEcCtD
Emtricitabine—Skin disorder—Doxorubicin—thyroid cancer	0.000781	0.0008	CcSEcCtD
Emtricitabine—Paraesthesia—Epirubicin—thyroid cancer	0.00078	0.000799	CcSEcCtD
Emtricitabine—Dyspnoea—Epirubicin—thyroid cancer	0.000775	0.000793	CcSEcCtD
Emtricitabine—Dyspepsia—Epirubicin—thyroid cancer	0.000765	0.000783	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00075	0.000768	CcSEcCtD
Emtricitabine—Fatigue—Epirubicin—thyroid cancer	0.000749	0.000767	CcSEcCtD
Emtricitabine—Pain—Epirubicin—thyroid cancer	0.000743	0.000761	CcSEcCtD
Emtricitabine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000732	0.00075	CcSEcCtD
Emtricitabine—Insomnia—Doxorubicin—thyroid cancer	0.000727	0.000744	CcSEcCtD
Emtricitabine—Paraesthesia—Doxorubicin—thyroid cancer	0.000722	0.000739	CcSEcCtD
Emtricitabine—Dyspnoea—Doxorubicin—thyroid cancer	0.000717	0.000734	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000711	0.000727	CcSEcCtD
Emtricitabine—Dyspepsia—Doxorubicin—thyroid cancer	0.000708	0.000725	CcSEcCtD
Emtricitabine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000694	0.000711	CcSEcCtD
Emtricitabine—Fatigue—Doxorubicin—thyroid cancer	0.000693	0.00071	CcSEcCtD
Emtricitabine—Urticaria—Epirubicin—thyroid cancer	0.00069	0.000707	CcSEcCtD
Emtricitabine—Pain—Doxorubicin—thyroid cancer	0.000688	0.000704	CcSEcCtD
Emtricitabine—Abdominal pain—Epirubicin—thyroid cancer	0.000687	0.000703	CcSEcCtD
Emtricitabine—Body temperature increased—Epirubicin—thyroid cancer	0.000687	0.000703	CcSEcCtD
Emtricitabine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000657	0.000673	CcSEcCtD
Emtricitabine—Hypersensitivity—Epirubicin—thyroid cancer	0.00064	0.000655	CcSEcCtD
Emtricitabine—Urticaria—Doxorubicin—thyroid cancer	0.000639	0.000654	CcSEcCtD
Emtricitabine—Abdominal pain—Doxorubicin—thyroid cancer	0.000636	0.000651	CcSEcCtD
Emtricitabine—Body temperature increased—Doxorubicin—thyroid cancer	0.000636	0.000651	CcSEcCtD
Emtricitabine—Asthenia—Epirubicin—thyroid cancer	0.000623	0.000638	CcSEcCtD
Emtricitabine—Pruritus—Epirubicin—thyroid cancer	0.000615	0.000629	CcSEcCtD
Emtricitabine—Diarrhoea—Epirubicin—thyroid cancer	0.000595	0.000609	CcSEcCtD
Emtricitabine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000592	0.000606	CcSEcCtD
Emtricitabine—Asthenia—Doxorubicin—thyroid cancer	0.000577	0.000591	CcSEcCtD
Emtricitabine—Dizziness—Epirubicin—thyroid cancer	0.000575	0.000588	CcSEcCtD
Emtricitabine—Pruritus—Doxorubicin—thyroid cancer	0.000569	0.000582	CcSEcCtD
Emtricitabine—Vomiting—Epirubicin—thyroid cancer	0.000552	0.000566	CcSEcCtD
Emtricitabine—Diarrhoea—Doxorubicin—thyroid cancer	0.00055	0.000563	CcSEcCtD
Emtricitabine—Rash—Epirubicin—thyroid cancer	0.000548	0.000561	CcSEcCtD
Emtricitabine—Dermatitis—Epirubicin—thyroid cancer	0.000547	0.00056	CcSEcCtD
Emtricitabine—Headache—Epirubicin—thyroid cancer	0.000544	0.000557	CcSEcCtD
Emtricitabine—Dizziness—Doxorubicin—thyroid cancer	0.000532	0.000544	CcSEcCtD
Emtricitabine—Nausea—Epirubicin—thyroid cancer	0.000516	0.000528	CcSEcCtD
Emtricitabine—Vomiting—Doxorubicin—thyroid cancer	0.000511	0.000523	CcSEcCtD
Emtricitabine—Rash—Doxorubicin—thyroid cancer	0.000507	0.000519	CcSEcCtD
Emtricitabine—Dermatitis—Doxorubicin—thyroid cancer	0.000506	0.000519	CcSEcCtD
Emtricitabine—Headache—Doxorubicin—thyroid cancer	0.000504	0.000516	CcSEcCtD
Emtricitabine—Nausea—Doxorubicin—thyroid cancer	0.000478	0.000489	CcSEcCtD
